DRUG-COATED BALLOONS HEALTHCARE PROFESSIONALS
Drug Coated Balloon
The IN.PACT™ Admiral™ drug-coated balloon (DCB) is a clinically proven, primary endovascular therapy used to treat femoropopliteal disease.ACCESS PRODUCT OVERVIEW
IN.PACT SFA Trial –
Primary Patency Outcomes
IN.PACT Admiral DCB demonstrates consistent positive outcomes out to 3 years.1
BEHIND THE OUTCOMES
IN.PACT Admiral DCB increases blood flow and reduces thickening of the artery wall by delivering the proven anti-proliferative drug paclitaxel to the vessel wall.
Average saved on follow-up costs through 2 years per patient with IN.PACT Admiral DCB versus standard PTA2
$2,984 vs. $4,196
Cost savings from the reduced rates of reintervention and higher rates of clinical efficacy make IN.PACT Admiral DCB the clear choice for patients and physicians.
Medtronic Data: 1-year Outcomes: IN.PACT Admiral IFU M052624T001 Rev. 1F. 2-year Outcomes: Laird et al, JACC, VOL . 6 6 , NO. 2 1 , 2 0 1 5. 3-year: Krishnan, P.VIVA, 2016. Primary patency is defined as freedom from clinically-driven TLR and freedom from restenosis as determined by DUS PSVR, ≤2.4 Primary Efficacy reported on Kaplan-Meier survival analysis.
Cohen D. Economic Outcomes of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons vs Standard PTA: 2-Year Results From the IN.PACT SFA II Trial. Presented at: VIVA 15; Nov. 2-5, 2015; Las Vegas.